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ABSTRACT
Background: Several studies have demonstrated the effectiveness and
cost-effectiveness of implantable cardioverter-deﬁbrillators (ICDs) in
chronic heart failure (CHF) patients. Despite its widespread use in devel-
oping countries, limited data exist on its cost-effectiveness in these settings.
Objective: To evaluate the cost-effectiveness of ICD in CHF patients
under the perspective of the Brazilian Public Healthcare System
(PHS).
Methods: We developed a Markov model to evaluate the incremental
cost-effectiveness ratio (ICER) of ICD compared with conventional
therapy in patients with CHF and New York Heart Association class II
and III. Effectiveness was evaluated in quality-adjusted life years (QALYs)
and time horizon was 20 years. We searched MEDLINE for clinical trials
and cohort studies to estimate data from effectiveness, complications,
mortality, and utilities. Costs from the PHS were retrieved from national
administrative databases. The model’s robustness was assessed through
Monte Carlo simulation and one-way sensitivity analysis. Costs were
expressed as international dollars, applying the purchasing power parity
conversion rate (PPP US$).
Results: ICD therapy was more costly and more effective, with incremen-
tal cost-effectiveness estimates of PPP US$ 50,345/QALY. Results were
more sensitive to costs related to the device, generator replacement fre-
quency and ICD effectiveness. In a simulation resembling the MADIT-I
population survival and ICD beneﬁt, the ICER was PPP US$ 17,494/
QALY and PPP US$ 15,394/life years.
Conclusions: In a Brazilian scenario, where ICD cost is proportionally
more elevated than in developed countries, ICD therapy was associated
with a high cost-effectiveness ratio. The results were more favorable for a
patient subgroup at increased risk of sudden death.
Keywords: chronic heart failure, cost-effectiveness, implantable
cardioverter-deﬁbrillators, primary prevention.
Background
Chronic heart failure (CHF) is nowadays recognized as a major
health problem, with increasing incidence and mortality in the
past few years [1–4]. In 2006, it was responsible for almost
300,000 admissions and nearly 50,000 deaths in Brazil [5].
Nearly half of these patients die because of fatal arrhythmia. The
implantable cardioverter-deﬁbrillator (ICD) is a device targeted
to terminate life-threatening arrhythmias, and has been studied
in patients with left ventricular systolic dysfunction for more
than two decades. After the MADIT-I trial [6] was published,
nine other trials have evaluated the beneﬁts of ICD in different
CHF populations [7–15], and a meta-analysis of these studies
has described a relative risk (RR) reduction of 25% for total
mortality [16].
Although ICD therapy has been consistently associated with
total death reduction in heart failure patients, its high cost pro-
hibits large scale implantation, even in developed countries. It is
estimated that more than 3 million North Americans meet eligi-
bility criteria from the MADIT-II trial (that is, previous myocar-
dial infarction and an ejection fraction of 30% or less) [17], and
this huge population makes a broad implantation unaffordable.
Several cost-effectiveness analyses have been reported aiming to
offer data to physicians and policymakers on the incorporation
of this technology [18–21]. However, most cost-effectiveness
studies were based on individual data from the trials—mostly
from MADIT-II [22–25]—or analyzed each trial separately [21].
Besides, none of them used cost data from developing country,
which are different from those in the United States, Canada, and
Europe.
In this report, we sought to evaluate the costs, effectiveness
and cost-effectiveness of ICD implant in a hypothetical cohort of
CHF patients with New York Heart Association (NYHA) func-
tional class II and III and a left ventricular ejection fraction
(LVEF) of 35% or less, applying cost and survival data from
Brazil. As a secondary objective, we evaluated the effect of clini-
cal and ICD related parameters in sensitivity analysis.
Methods
Target Population
The model assumed a baseline population of heart failure
patients, 60 years old, NYHA class II and III, LVEF  35%, and
independent of etiology. All patients were in primary prevention,
that is, none of them had a history of life threatening arrhyth-
mias. The choice of our target population characteristics was
intended to reproduce the clinical features of the majority of
patients included in the ten aforementioned trials. We incorpo-
rated in the model patients with NYHA functional class II or III,
considering that the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT) [15]—the largest ICD trial—had only patients with
NYHA class II and III, and more than 80% of patients studied in
the other trials were in these functional classes.
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Decision Model Structure
We constructed a decision tree model with Markov transitional
states using DATA Pro (TreeAge Software, Version 5.0, Inc.
Williamstown, MA). The model tracked a hypothetical cohort of
CHF patients over time who received an ICD plus conventional
therapy—optimal pharmacological treatment—or conventional
therapy alone (Fig. 1). We decided to evaluate only single
chamber ICD, because of its equal efﬁcacy, smaller cost, and
lower rate of complications when compared with double
chamber devices.
The structure of our model is similar to the one constructed
by Banz et al., who evaluated the cost-effectiveness of cardiac
resynchronization therapy [26]. Patients in conventional treat-
ment could remain stable or die in each yearly cycle. In the ICD
arm, patients could suffer operative death or survive the proce-
dure. Surviving patients could have implantation failure, when
they entered a Markov process identical to conventional treat-
ment, or could have a successful implantation, being susceptible
to minor procedure-related complications, such as pneumotho-
rax or deep vein thrombosis. Both patients with and without
these complications entered a Markov process that simulated the
natural history of patients treated with ICD. During each one
year cycle, patients in this path could remain stable, experience
any ICD complication or die. ICDs would have their generator
replaced every 5 years in the base case, with a maximum replace-
ment of three times.
Complications included in the model were infection—
which demanded ICD replacement, in case of survival—lead
dislodgement, break, or an insulation defect. We constructed
the model using all cause mortality instead of stratifying death
by cardiovascular or other causes, since most of the evidence
about ICD efﬁcacy reports total mortality reduction. A sche-
matic representation of the decision tree is displayed in
Figure 1.
The discount rate for both costs and effectiveness was 3% per
year. We used the public third party payer perspective and a
20-year time horizon.
Survival Data
In order to build a model with reliable data regarding the natural
history of heart failure in Brazil, we used data from a local cohort
of heart failure patients followed by a heart failure team [27,28],
whose characteristics are similar to the populations studied in the
ICD clinical trials, specially SCD-HeFT and MADIT-II. This
cohort was comprised of 386 subjects (63% male), with a
median age of 59 years (interquartile range [IQR] 49–68) and
had a median follow-up of 35 months (IQR 18–60). Forty-one
percent of these patients had ischemic heart disease as the etiol-
ogy of heart failure. There were 53% of patients with hyperten-
sion, 33% with diabetes, and 13% with current use of tobacco;
89% were on angiotensin-converting enzyme inhibitors and 73%
were on beta blockers. None of the patients were either on ICD
or cardiac resynchronization therapy. Considering the small
number of patients with a follow-up longer than 7 years in this
cohort, we needed to project survival beyond this time point. We
undertook a comparison between the survival curve of this
cohort and from the adult Brazilian population, in order to
identify which mathematical function would best ﬁt the data.
Exponential function (compared to linear and quadratic) best
ﬁtted the curves, judged by its higher r2, and was therefore chosen
for survival modeling. The ﬁnal equation for survival prediction
was Y = 0.000387 * (EXP[X * 7.922]), where X is the survival
function for an individual from the general population at a given
age, Y is the estimated survival for a heart failure patient at that
given age, 0.000387 is the intercept of the function and 7.922 is
the b coefﬁcient. Survival function from general population was
calculated with a Cox model, using data from National Demo-
Figure 1 Schematic representation of the decision model. Patients with heart failure can either stay on conventional therapy or undergo implantable cardioverter-
deﬁbrillator (ICD) implantation. Patients assigned to ICD can suffer operative death or implant failure. Patients with successful implant can suffer minor
procedure-related complications. After the acute phase, patients enter a Markov process that includes most common ICD chronic complications. Patients in the
conventional arm also enter a Markov model of chronic heart failure (CHF).
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graphic Census. Given the fact then the census has stratiﬁed
mortality data only up to 79, the model’s time horizon was set to
20 years.
Effectiveness Data
Clinical outcomes considered in the model were life years saved
(LYS) and quality-adjusted life years (QALY). The base case was
modeled using the later, as recommended by the Panel on Cost
Effectiveness [29].
We searched MEDLINE for clinical trials and meta-analyses
of ICD therapy in heart failure patients in order to obtain ICD
effectiveness estimates. There are two meta-analyses published
compiling data from ten primary prevention trials available.
Al-Khatib et al. found a hazard ratio for total mortality of 0.71
(95% conﬁdence interval [CI] 0.58–0.88), and an I2 of 70% [30].
This large heterogeneity was the reason given by Sanders et al. to
analyze each trial separately in their cost-effectiveness report
[21]. Nanthakumar et al. pooled the results from the 10 studies
and estimated an RR of 0.75 (95% CI 0.63–0.91), also with a
high heterogeneity (I2 of 69%) [16]. They attributed this ﬁnding
to three trials with design very different from the other seven: the
DINAMIT trial [14], which included patients with recent myo-
cardial infarction (maximum 40 days); the MUSTT trial [8],
which was not a randomized comparison of ICD use, and the
coronary artery bypass graft patch [7] trial, in which the device
was implanted during a scheduled coronary artery bypass
surgery. A second analysis excluding these three trials (which
comprised approximately 30% of the total sample) yielded a
similar RR of 0.74 (95% CI 0.67–0.83) and a very low hetero-
geneity (I2 of 5.2%). For the current analyses, we decided to use
the latter risk reduction in our base case.
Complications
For complications of ICD therapy, the evidence search comprised
clinical trials, cohort studies and international registries. In order
to best reﬂect these data under the use of present-day technology
and expertise, we included only studies published since 1996,
when the majority of lead systems were implanted transvenously.
A meta-analysis conducted by Ezekowitz et al. [31] provided
rates for system infection (total number of patients = 12,436),
peri-implantation mortality (N = 39,858, deﬁned as mortality in
the ﬁrst 30 days following the procedure) and implantation
failure (N = 11,129).
We performed random effects meta-analyses in order to cal-
culate probabilities for lead dislodgement and death associated
with ICD infection, using the incidence rates from individual
studies. We included studies with at least 90% of ICDs with
pectoral implants; there were four reporting lead dislodgement
[32–35] and four reporting device infection-related mortality
[9,32,33,36]. Meta-analyses were performed in Stata (version 9,
Stata Corporation, College Station, TX).
Probabilities for lead dislodgement were applied only during
the cycle immediately after ICD implantation, as this kind of
complication rarely occurs after this period. If the patient under-
went a new implant during the Markov process, after an infec-
tion, he would be at risk of lead dislodgement for another cycle.
Probabilities for system infection were applied throughout the
20-year time horizon.
Data input for lead complications requiring its replacement
(such as breaks and insulation defects) were collected from a
work by Kleemann et al., which followed a cohort of patients up
to 10 years [37]. We chose to use data solely from this article
instead of a compilation of all evidence available since this study
showed a progressive increase in the rate of this complication
over time, what was already suggested by Luria et al. in an
analysis with fewer patients [38]. As the number of patients
accompanied for more than seven years was very small, we used
the yearly rate until the 7th year presented in the study, and
applied the rate of the seventh cycle to all remaining cycles in the
model. Because our model simulates patients with single chamber
ICDs, we did a transformation of the annual rates presented by
the study, using the hazard ratio presented to single versus double
chamber ICDs regarding this complication (0.69) and the
number of single chamber ICDs implanted (46.6%). Our calcu-
lations generated a formula by which the annual rate of lead
change for single chamber device was equal to the study value for
a double chamber divided by 1.24.
Utilities
Utility data regarding CHF patients vary considerably in the
literature, and we could not identify a quality of life study using
appropriate methodology performed in Brazilian patients.
Although other studies have described utility values as low as
0.52 for NYHA class III [39], we chose the utility value of 0.88
generated in the Beaver Dam Study [40], which was also adopted
by Al-Khatib [24] and Sanders [21,23,41] in their analysis.
Inappropriate shocks associated with ICD can affect quality
of life [42,43]. In the Cardiac Arrhythmia Patient Outcomes
Research Team study, mean utility for low, moderate, and severe
rates of device-related side effects were 0.76, 0.75, and 0.64,
respectively [44]. Although this adverse effect on quality of life,
two large studies, one evaluating patients from the SCD-HeFT
and the other from the DEFINITE trial, did not observe any
difference in quality of life in the comparison of ICD and con-
ventional therapy patients [45,46]. These ﬁndings lead us to not
incorporate any changes in quality of life in the ICD paths in our
base case, although we considered these scenarios in our sensi-
tivity analysis, where we ranged ICD utility from 0.88 (the same
as in the conventional therapy) to 0.64, the lowest value
described in the literature.
Costs
Annual costs of conventional therapy were derived from a cohort
study of ambulatory patients from Southeastern Brazil [47]. We
used their resource utilization data to calculate costs from the
Public Healthcare System (PHS) perspective. PHS costs included
expenditures with diagnostic tests, laboratory exams, hospi-
talizations, medical visits, and all medications paid by the
government.
Medication costs were based on Brazilian retail sales price.
Prices of medical visits, hospitalizations, ICD placement and
complications, and laboratory and imaging tests were derived
from codebooks (year 2007) used by the PHS for reimbursement
in Brazil. These values have a ﬁxed diagnoses (or procedure)
related group price, that is, the PHS reimburse the same amount
for a hospitalization for worsening heart failure, regardless of
diagnostic work-up and therapies prescribed; this applies to ICD
related costs. Costs are expressed in Brazilian Real (R$) and
international dollars, applying the purchasing power parity con-
version rate (PPP US$). In this procedure, the purchase power of
money in different countries is taken into account, which is more
appropriate than a simple exchange rate. According to the last
report of the World Bank regarding conversion rates, 1 PPP
US$ = 1.357 R$ [48].
Sensitivity Analyses
We performed one-way sensitivity analysis on most parameters in
the model (Table 1). Rates of ICD effectiveness, perioperative
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death, system infection and its associated mortality, implantation
failure, and lead dislodgement were varied between the bound-
aries of the meta-analyses conﬁdence intervals [16,31]. Lead
change rates were varied among their original values. Costs were
varied between  50% of their original values and discount for
both costs and utilities between 0% and 7%. Battery replacement
frequency was oscillated between 3 and 7 years. Utilities varia-
tion was applied as described earlier.
We also performed an analysis modifying the survival curve in
order to simulate the model in a population similar to the
MADIT-I trial, which comprehended patients at higher risk of
ventricular arrhythmias, changing the a and b in the exponential
equation to 0.000367 and 7.762, respectively. Accordingly, we
used the RR associated with ICD therapy achieved in that study
(RR 0.41; 95%CI 0.24–0.69) [16].
The robustness of the model was tested in a Monte Carlo
simulation, with generation of 1000 trials and variation of values
in the range described earlier. The distributions used in the simu-
lation were beta for probabilities, normal for the logarithm of
RR, and triangular for costs. We also performed threshold analy-
sis of the cost of the ICD in different clinical scenarios. Table 1
lists the base case assumptions and the range used in sensitivity
analysis.
Results
For the base-case analysis, in the model starting at 60 years of
age for patients with CHF class II or III, the predicted mean
survival was 5.95 years with conventional treatment, 6.99 with
ICD therapy, diminishing to 5.23 and 6.15 when adjusted for
quality, respectively. The survival curve is shown in Figure 2.
The undiscounted effectiveness gained for ICD compared with
conventional therapy was 1.42 life-years and 1.24 QALYs.
Total costs of therapy were PPP US$ 24,619 for conventional
and PPP US$ 70,841 for ICD therapy. Table 2 shows the health
beneﬁts—expressed in LYS and in QALYs—the costs of each
strategy, and the incremental cost effectiveness ratio (ICER).
ICD therapy was both more expensive and effective when
compared with conventional therapy, yielding an incremental
cost-effectiveness ratio of PPP US$ 50,345 (R$ 68,318) per
QALY and PPP US$ 44,304 (R$ 60,121) per LYS in the base
case.
In order to simulate the natural history of a heart failure
population with increased risk of sudden death, resembling
patients evaluated in the MADIT-I trial, we changed the survival
curve and effectiveness parameters as described in the Methods
section. In this analysis, we obtained a predicted mean survival of
4.37 QALYs in the conventional treatment arm and 7.63 QALYs
in the ICD therapy. Survival curves of this simulation are dis-
played in Figure 2. In this scenario, the ICER decreased to PPP
US$ 17,494 (R$ 23,739) per QALY and PPP US$ 15,394 (R$
20,890) per LYS.
One-way sensitivity analyses are displayed in Table 3. Results
were most sensitive to ICD and generator costs, generator
replacement frequency, ICD effectiveness, and utility of a patient
with ICD. Discount rate and utility of a patient with heart failure
had moderate effect on the incremental cost-effectiveness ratio,
and the remaining parameters had minimal effect on the overall
result. If the utility of a patient with an ICD was set to 10%
lower than patients in the conventional treatment, the ICER
would become PPP US$ 149,665, and the ICD strategy would
eventually be dominated with utilities for ICD patients 16%
lower than conventional therapy patients. In the MADIT-I
model, altering the RR of death associated with ICD from 0.24
Table 1 Input variables, values, and sources
Input variable Base-case Variation for sensitivity analysis Source
ICD variables
Procedural death (%) 1.3 1.2–1.4 [31]
Frequency of generator replacement (y) 5 3–7
Risk reduction relative to conventional treatment (%) 26 17–33 [16]
Annual probability of system infection (%) 0.6 0.5–0.8 [31]
Annual probability of lead change (%) [37]
1st year 2.36 2.36–2.93
2nd year 1.62 1.62–2.01
3rd year 2.09 2.09–2.59
4th year 2.19 2.19–2.71
5th year 3.16 3.16–3.92
6th year 5.44 5.44–6.75
7th through 20th year 6.72 6.72–8.33
Lead dislodgement (%) 3.48* 1.92–5.23 [32–35]
Mortality associated with infection (%) 21 0–50 [9,32,33,36]
Implantation failure (%) 1.1 0.9–1.3 [31]
Minor procedure related complications† 0 0–4 [32]
Costs (PPP US$)
Initial ICD implantation, total costs 22,447 11,223–33,669
Generator replacement 21,671 10,836–32,507
Admission for lead replacement 5,596 2,798–8,394
Admission for lead repositioning 290 145–435
Admission for system infection (additional)‡ 1,123 0–2,245
Annual cost of heart failure treatment 2,329 1,164–3,493
Extra annual cost for ICD follow-up 16 8–24
Utilities
Utility of a patient with heart failure 0.88 0.71–0.88 [21,23,24,41,57]
Utility of a patient with heart failure and ICD 0.88 0.64–0.88 [41]
Discount rate (%) 0–7
*Mean value calculated with incidence rates meta-analysis, random effect model from DerSimonian and Laird.
†Minor peri-implant complications include pneumothorax, lower limbs deep vein thrombosis and brachial thrombosis.
‡Additional cost for system infection, considering that a patient with this complication would be admitted for treatment of infection and implantable cardioverter-deﬁbrillator (ICD) change,
and would generate a cost of at least the same as the one for ICD implant.
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to 0.69 yielded cost-effectiveness ratios of PPP US$ 13,496
(R$ 18,314) and PPP US$ 34,635 (R$ 47,000) per QALY,
respectively.
Figure 3 shows two-way sensitivity analyses. If the effective-
ness of ICD, represented by RR reduction, associated with the
ICD increases to 30% and the generator cost is reduced by 25%,
ICER would also have a considerable decrease, achieving PPP
US$ 32,779 (R$ 44,481) per QALY (Fig. 3a). If the generator
replacement frequency increases to 6-year intervals and the ICD
cost falls by 25%, ICER would drop to PPP US$ 35,141 (R$
47,686) per QALY (Fig. 3b).
In the Monte Carlo simulation, we evaluated the number of
simulations that fell below the threshold of PPP US$ 27,495 (R$
37,311), which represents three times the Brazilian gross domes-
tic product (GDP) per capita in 2006 [49], according to the
World Health Organization (WHO) recommendation [50].
Figure 4 shows the 1000 trials produced in the base case analysis;
only 2% of them fell below this threshold. Conversely, in the
Monte Carlo simulation with MADIT-I parameters, 84% of
trials fell below PPP US$ 27,495 per QALY.
Discussion
In this study, we developed a decision model to evaluate the
cost-effectiveness of primary ICD in CHF patients in Brazil, and
the results show that the incremental cost-effectiveness ratio of
ICD implant versus optimal medical therapy was elevated, reach-
ing PPP US$ 50,345 per QALY and PPP US$ 44,304 per LYS.
Our analysis suggested that the model was robust, being more
sensitive to ICD related costs and battery replacement frequency.
In a scenario of increased risk of arrhythmias, cost-effectiveness
was favorable for ICD therapy.
The results obtained were in the range of similar evaluations
conducted in the United States. In the works by Sanders [21],
Figure 2 Undiscounted survival curve projec-
tions for conventional treatment and implantable
cardioverter-deﬁbrillator (ICD) therapy in the
base case analysis and in the simulation resembling
MADIT-I population.
Table 2 Model predicted cost, effectiveness, and cost-effectiveness of
competing strategies
Total cost
(US$ PPP)
Effectiveness
Incremental
cost-effectiveness
Mean life
years
Mean
QALYs
US$
PPP/LYS
US$
PPP/QALY
Conventional
treatment
24,619 5.95* 5.23* — —
ICD therapy 70,841 6.99* 6.15* 44,304 50,345
*All values are discounted.
ICD, implantable cardioverter-deﬁbrillator; LYS, life years saved; QALY, quality-adjusted life
year; US$ PPP, purchasing power parity conversion rate.
Table 3 One-way sensitivity analysis*
Variables
Lower ICER
(US$ PPP/QALY)
Higher ICER
(US$ PPP/QALY)
Mortality reduction with ICD 38,300 83,678
Probability of system infection 49,751 51,561
Probability of death for system
infection
48,245 53,570
Probability of procedural death 50,048 50,646
Probability of implantation failure 50,286 50,404
Probability of minor peri-implant
complications
50,337 50,353
Probability of lead dislodgement 50,338 50,352
Probability of lead replacement 50,345 50,851
Utility of a patient with heart failure 50,345 62,399
Utility of a patient with heart failure
and ICD
50,345 Dominated
Discount rate 41,994 63,691
Battery replacement frequency 29,016 72,087
Cost of ICD implant and battery
replacement†
26,831 73,857
Cost of heart failure optimal
treatment per year
49,021 51,668
Cost of electrode replacement 49,290 51,400
Cost of system infection 50,285 50,405
Cost of ICD maintenance 50,303 50,387
Cost of lead dislodgement 50,338 50,352
Cost of minor peri-implant
complications
50,341 50,349
*Parameter ranges as described in Table 1.
†Cost of battery replacement was considered as 96.54% of ICD implant cost, and variation
in the later fell on both parameters.
ICD, implantable cardioverter-deﬁbrillator; ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life year; US$ PPP, purchasing power parity conversion rate.
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Al-Khatib [24], and Zwanziger [25], whose model’s assumptions
were based on the MADIT-II trial, cost-effectiveness ratios were
US$ 39,000, 50,500 and 78,000 per LYS, respectively. In the
study by Mark, with data from SCD-HeFT, ICER was US$
41,530 per QALY [18]. In another work by Sanders, where
analyses were made separately for six primary prevention
trials, ICER ranged from US$ 34,000 to US$ 70,200 per QALY
[21].
Even though the absolute value of the ICER was similar to
American studies and was close to values accepted as cost-
effective in some developed countries, the parameters applied to
deﬁne a technology as cost-effective vary worldwide. The ICER
found in our study was elevated when compared to the WHO
suggested benchmark, which is three times the GDP per capita of
a country, namely PPP US$ 27,495 (R$ 37,311) for Brazil in
2006. In sensitivity analyses, the ICER would fall below this ratio
only if ICD implant and generator cost would be reduced by
50%, and would get close to this value if the generator replace-
ment frequency increased to 7 years intervals. All other param-
eters did not decrease substantially the ICER in the most
favorable boundaries.
In the analysis where we projected a worst survival curve
and used effectiveness data from the MADIT-I trial, where the
population had a higher risk of ventricular arrhythmias, the
ICER was much more favorable, and remained below the
selected threshold in 84% of trials in the Monte Carlo simu-
lation. Some details of this trial, however, suggests that it does
not represent current standard of HF care—for example, use of
beta-blockers was very low in the conventional treatment, what
could have negatively biased the survival curve exaggerating the
perceived efﬁcacy of the ICD [51]. It is particularly disturbing
that the conventional and ICD groups were slightly unbalanced
in the end of the trial concerning beta-blockers use. However,
although we acknowledge that the treatment received by the
patients in that trial was suboptimal in both groups, the ICER
in our MADIT-I scenario was far below the WHO’s suggested
threshold. This makes us believe that patients with similar clini-
cal characteristics as that included in the MADIT-I trial, even if
treated optimally, would still present an economically accept-
able ICER for ICD implant.
Our study was based on data from almost 400 patients from
a Brazilian heart failure cohort, and survival estimates were
derived from local data. In previous studies, we have demon-
strated that overall heart failure patients from Brazil had similar
characteristics to the populations studied in the ICD clinical trials
and other international cohorts [28,52]. It is important to
emphasize that in this cohort only a small percentage of patients
had Chagas’s disease (<10%), which may not be representative
of other regions of the country. There is a great debate in the
literature whether ICD therapy holds similar beneﬁt among
patients with Chagas’disease [53], so that this results might not
hold on these patients.
Besides using data from Brazilian population, the model was
built using meta-analysis data for both effectiveness and compli-
cations, progressive rates of complications over time, especially
the ones requiring lead change. The extended time horizon of our
Figure 3 Two-way sensitivity analysis. (a) Implant-
able cardioverter-deﬁbrillator (ICD) costs versus
ICD effectiveness. (b) ICD costs versus generator
replacement interval. Lines represent different
ICD cost value inputs, ranging 25% and 50% more
or less than base-case value (purchasing power
parity conversion rate US$ 22,447).
Cost-Effectiveness of ICD in Brazil 165
analytic strategy is also an important feature, since it has the
ability to capture almost all costs and beneﬁts yielded by each
therapy.
The effectiveness parameter we used in the current evaluation
came from a meta-analysis that included the COMPANION
study, which evaluated heart failure patients with severe func-
tional disability (class III and IV) and had a more complex device
implanted, with resynchronization capacity. However, removing
this study from the meta-analysis, the ICD would have a mortal-
ity beneﬁt of 28% (95% CI 18–36%), yielding an ICER of PPP
US$ 46,211/QALY, similar to the one we found using the original
result. One also could argue whether the meta-analysis of com-
plications that we used was an adequate strategy [31], as some of
the patients included were not exactly the ones in the population
we wished to simulate. However, this study is the best evidence
about complications published to date, and, as seen in sensitivity
analysis, those parameters had minimal inﬂuence on the results.
In a Brazilian study reporting 26-month follow-up of a cohort of
155 patients who had an ICD implanted [54], ICD clinical effec-
tiveness, including complications, was similar to the ones
described in our study.
In the last decade, health economics evaluation has increased
in importance to policymakers and clinicians in assessing health-
care services and technologies in developing countries. Although
there is no formal evaluation on the difference between high- and
low-cost settings, it is rational to assume that lower labor costs
and human capital may impact favorably on cost-effectiveness
ratios of new interventions. This may be true to interventions
involving low cost technology and high overall labor cost, such
as demonstrated for screening programs for diabetes [55]. None-
theless, in scenarios whether new technologies are associated
with signiﬁcant high costs and do not reduce or avert human
cost, they tend to show elevated cost-effectiveness ratios. The
case observed for drug-eluting stents [56] and in this article for
ICD therapy for heart failure patients.
It is important to recognize some caveats associated with
ICD economic analyses. For instance, we considered the beneﬁt
of ICD constant over time, which can overestimate its beneﬁts
as other cause of deaths have a tendency to grow with increas-
ing age, decreasing the proportion of deaths due to arrhythmia.
To overcome this problem, it would be necessary a clinical trial
with extended follow-up, and available data from clinical trials
so far have a follow-up of 5 years or less. In addition, there
were no national data on utilities for heart failure, which might
be different from one country to another. Thus, our result in
QALYs might not be a perfect estimate for the Brazilian popu-
lation. Finally, our analysis is limited to the PHS perspective,
not including some costs that would be counted in the societal
perspective.
This study represents a valuable tool for policymakers,
although cost-effectiveness analyses should not be the only basis
for decision making in health-care resource allocation. Strategies
aiming at cost reduction of ICD should be pursued, in order to
generate more favorable cost-effectiveness ratios for a larger
number of patients. Considering present-day thresholds of
acceptable cost-effectiveness ratios, ICD implantation should be
strongly considered for patients at very high risk for ventricular
arrhythmias in this Brazilian scenario, but usage in other eligible
populations should be evaluated carefully.
Source of ﬁnancial support:This project received ﬁnancial support from
Conselho Nacional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq).
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Figure 4 Monte Carlo 1000 trials scatter plot.The number of points below the threshold lines, from bottom to top, are as follows: 2.6% (line 1: purchasing power
parity conversion rate [PPP US$] 27,495/QALY [three times Brazil’s gross domestic product [GDP] per capita]), 37.5% (line 2: PPP US$ 45,825/QALY [ﬁve times
Brazil’s GDP per capita]), and 77.1% (line 3: PPP US$ 64,155/QALY [seven times Brazil’s GDP per capita]).
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